PET/MRI for Men Being Considered for Radiotherapy for Suspected Prostate Cancer Recurrence Post-Prostatectomy

NACompletedINTERVENTIONAL
Enrollment

99

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

January 31, 2017

Study Completion Date

January 31, 2021

Conditions
Prostate Cancer
Interventions
DEVICE

18F-FCH PET/MRI Scan

Patients will first undergo screening to ensure eligibility. If eligible, they will undergo a PET/MRI scan using 18F-FCH as the radiolabeled tracer. If prostate cancer is detected outside the prostate, patients may undergo a biopsy or follow-up 18F-FCH PET/MRI to confirm the results.

Trial Locations (10)

2010

St. Vincent's Hospital, Sydney

3002

Peter MacCallum Cancer Centre, Melbourne

3084

Austin Hospital, Melbourne

3128

Eastern Health, Melbourne

N6A 5W9

Lawson Health Research Institute, London Health Sciences Centre, London

M5G 2M9

University of Toronto, Toronto

G1V 0A6

Universite Laval Quebec, Laval

Unknown

Velindre Cancer Centre, Cardiff

NW1 2BU

University College London Hospital, London

SW3 6JJ

Royal Marsden Hospital, London

All Listed Sponsors
lead

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

OTHER

NCT02131649 - PET/MRI for Men Being Considered for Radiotherapy for Suspected Prostate Cancer Recurrence Post-Prostatectomy | Biotech Hunter | Biotech Hunter